FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

A meta-analysis of 25 studies—totaling over 5,000 participants—focused on a question that has been troubling patients, physicians, and regulators: Does treatment with CAR T-cell therapy contribute to the development of secondary cancers?

September 13, 2024

Vol.50 No.34

By McKenzie Prillaman

Clinical Roundup

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

People with operable non-small cell lung cancers may fare better over the next few years by receiving immunotherapy treatments before and after surgery instead of only before surgery, according to an analysis by Johns Hopkins Kimmel Cancer Center investigators.

September 13, 2024

Vol.50 No.34

Drugs & Targets

FDA grants Orphan Drug designation to elraglusib for soft tissue sarcomas

FDA has granted orphan drug designation for the GSK-3β inhibitor elraglusib, for treatment of soft tissue sarcoma.

September 13, 2024

Vol.50 No.34

Drugs & Targets

FDA seeks consumer representatives for the Oncologic Drugs Advisory Committee

FDA is seeking consumer representatives to serve on the Oncologic Drugs Advisory Committee.

September 13, 2024

Vol.50 No.34

Clinical Roundup

UTSW study reveals widespread disparities in immunotherapy use for patients with advanced kidney and bladder cancers

A study led by researchers at UT Southwestern Medical Center reveals significant disparities across the country in the use of immunotherapy for patients with advanced kidney and bladder cancers.

September 06, 2024

Vol.50 No.33

Drugs & Targets

FDA approves Rybrevant + Lazcluze for NSCLC

FDA approved Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.

September 06, 2024

Vol.50 No.33

FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy

YOU MAY BE INTERESTED IN

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

FDA grants Orphan Drug designation to elraglusib for soft tissue sarcomas

FDA seeks consumer representatives for the Oncologic Drugs Advisory Committee

UTSW study reveals widespread disparities in immunotherapy use for patients with advanced kidney and bladder cancers

FDA approves Rybrevant + Lazcluze for NSCLC

Renew today!

Subscriber content

Can you spare 10 minutes to complete a survey?

Login

FDA approves Tecentriq Hybreza for subcutaneous PD-(L)1 cancer immunotherapy

YOU MAY BE INTERESTED IN

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis showsSubgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies

Immunotherapy before and after lung cancer surgery reduces death risk, disease recurrence

FDA grants Orphan Drug designation to elraglusib for soft tissue sarcomas

FDA seeks consumer representatives for the Oncologic Drugs Advisory Committee

UTSW study reveals widespread disparities in immunotherapy use for patients with advanced kidney and bladder cancers

FDA approves Rybrevant + Lazcluze for NSCLC

Can you spare 10 minutes to complete a survey?

Login

Factors outside CAR T-cell therapy are associated with increased risk of secondary cancers after the treatment, meta-analysis shows
Subgroup analysis suggests risk of secondary cancers after CAR T-cell therapy is similar to risk after other therapies